Bedrijfsoverzicht
Indivior Pharmaceuticals, Inc. is primarily engaged in the development, manufacture, and sale of buprenorphine-based prescription drugs designed for the treatment of opioid dependence and related disorders across the United States, Europe, Canada, Australia, and international markets. The company operates within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical products rather than mass-market consumer goods. As of the latest available data, the firm carries a market capitalization of $3.82B and reports an annual revenue (TTM) of $1.24B, employing a workforce of 827 individuals. These financial figures indicate that Indivior holds a significant position within its niche, supported by a substantial asset base that allows for continued investment in its specialized drug portfolio while maintaining a mid-sized operational footprint relative to large-cap pharmaceutical peers.
Financiële gezondheid
The company reported a revenue of $1.24B for the trailing twelve months, generating a net income of $210.00M and an EBITDA of $397.00M. The substantial gap between the $1.24B revenue and the $210.00M net income reveals a robust cost structure where the company retains a significant portion of its earnings as profit before interest and taxes, though the EBITDA of $397.00M further highlights strong operational profitability before financing and non-cash expenses. Indivior generated free cash flow of $221.75M, which signifies a high degree of financial flexibility allowing the company to fund operations, repay debt, or pursue strategic initiatives without relying heavily on external capital markets. The gross margin stands at 84.0%, indicating high pricing power or low cost of goods sold typical of branded specialty drugs; the operating margin of 37.2% demonstrates efficient management of operating expenses, while the profit margin of 16.9% reflects the final impact of interest, taxes, and other non-operating items on the bottom line. In terms of liquidity and leverage, the company holds $195.00M in cash against $351.00M in debt, resulting in a debt-to-equity ratio listed as N/A due to the specific accounting treatment of its equity structure. The current ratio is 0.71, which indicates that the company's current assets are less than its current liabilities, suggesting a reliance on long-term financing or specific asset liquidation strategies to meet short-term obligations rather than a strictly conservative liquid stance. Furthermore, the Return on Equity is listed as N/A, while the Return on Assets is 19.2%, a metric that reveals how effectively management utilizes the company's total asset base to generate earnings independent of the capital structure's leverage.
Waarderingsbeoordeling
The stock carries a trailing P/E ratio of 18.62 and a forward P/E of 8.87, and the significant difference between these two metrics implies that the market expects a substantial expansion in future earnings that would compress the valuation multiple in the coming years. The price-to-book ratio is -38.95, which indicates an abnormal valuation state where the market price is far below the book value, often seen in companies with substantial goodwill, intangible assets, or specific accounting adjustments that result in negative equity on the books. Alternative valuation metrics such as the price-to-sales ratio of 3.08 and the EV/EBITDA of 10.01 suggest that the company is valued at a premium relative to its sales but at a moderate multiple of its earnings before interest, taxes, depreciation, and amortization, reflecting confidence in its future cash generation capabilities. Regarding trading range, the 52-week high was $38.00 and the 52-week low was $8.69, meaning the current price sits at a level that requires calculation relative to this wide historical range to determine the precise percentage deviation from the peak or trough. The beta value is 1.21, which explains that the stock exhibits higher price volatility relative to the broader market, moving more aggressively than the S&P 500 during periods of market stress or rally, a characteristic common in small-cap biopharmaceutical stocks.
Growth & Income
Indivior demonstrated revenue growth of 19.7% year-over-year and earnings growth of 376.2% year-over-year, and the fact that earnings are growing significantly faster than revenue implies that the company is benefiting from margin expansion, cost synergies, or a shift in its product mix toward higher-margin offerings. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests its substantial earnings and free cash flow into growth initiatives, research and development, or debt reduction rather than distributing income to shareholders. This retention of earnings supports the aggressive earnings growth trajectory observed, prioritizing capital allocation for expansion over immediate income generation for investors. Overall, the company's growth and income profile is characterized by exceptional earnings acceleration and a zero-dividend policy, positioning it as a growth-oriented investment within the healthcare sector that relies on capital appreciation rather than yield for shareholder returns.